We rank companies based on fund manager, research analyst and news sentiment
BIB

ProShares Ultra NASDAQ Biotechnology
BIB

$48.01
1.92%
0
Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

114% more call options, than puts

Call options by funds: $2.59M | Put options by funds: $1.21M

35% more capital invested

Capital invested by funds: $5.89M [Q3] → $7.94M (+$2.05M) [Q4]

1.59% more ownership

Funds ownership: 7.23% [Q3] → 8.81% (+1.59%) [Q4]

0% more funds holding

Funds holding: 20 [Q3] → 20 (+0) [Q4]

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

Research analyst outlook

We haven’t received any recent analyst ratings for BIB.

Financial journalist opinion